Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Wanrui Lv"'
Publikováno v:
Frontiers in Medicine, Vol 11 (2024)
IntroductionThe identification of risk factors for regional lymph node (r-LN) metastasis in rectal neuroendocrine tumors (R-NETs) remains challenging. Our objective was to investigate the risk factors associated with patients diagnosed with R-NETs ex
Externí odkaz:
https://doaj.org/article/8ce3bf986eb24912950b8be647b11b0b
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Pancreatoblastoma (PB), a neoplasm derived from pancreatic follicular cells, primarily affects the pediatric population. Although infrequent in adults, it is associated with a considerably worse prognosis. Approximately one-third of patients are diag
Externí odkaz:
https://doaj.org/article/f2c593e66bdd4f4a8a584a93884602a9
Publikováno v:
BMC Neurology, Vol 23, Iss 1, Pp 1-6 (2023)
Abstract Background Immune checkpoint inhibitor (ICI) combined with chemotherapy has exhibited promising results in small sample studies of pancreatic cancer patients. The efficacy of toripalimab, a programmed cell death protein 1 (PD-1) monoclonal a
Externí odkaz:
https://doaj.org/article/48596661be984dbebb00831a38c76074
Autor:
Ruizhen Li, Ke Cheng, Xiaofen Li, Chen Chang, Wanrui Lv, Li Xiaoying, Pei Zhang, Heqi Yang, Dan Cao
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Epstein-Barr virus-associated lymphoepithelioma-like intrahepatic cholangiocarcinoma (EBVa LEL-ICC) is a rare tumor, characterized by a rich tumor immune microenvironment (TIME). While this tumor is reportedly sensitive to immunotherapy, its response
Externí odkaz:
https://doaj.org/article/e207fa4750c3449bb5046e7b291a8c06
Autor:
Pei Zhang, Heqi Yang, Kaiguo Zhu, Chen Chang, Wanrui Lv, Ruizhen Li, Xiaoying Li, Tinghong Ye, Dan Cao
Publikováno v:
Biomedicines, Vol 11, Iss 11, p 2884 (2023)
Solute carrier family 31 member 1 (SLC31A1) encodes a protein that functions as a homotrimer for the uptake of dietary copper. As a vital member of the cuproptosis gene family, it plays an essential role in both normal tissues and tumors. In this stu
Externí odkaz:
https://doaj.org/article/435355415767416886a38d3fadb2cbd0
Publikováno v:
BMJ Open, Vol 12, Iss 7 (2022)
Introduction The optimal dose and treatment modality of neoadjuvant radiotherapy applied for treating borderline resectable and locally advanced pancreatic ductal adenocarcinoma (PDAC) have been debated topics in oncology. The objective of the presen
Externí odkaz:
https://doaj.org/article/c861e28fec464c58a6775339b2964408
Publikováno v:
Frontiers in Oncology, Vol 11 (2022)
Some pertinent studies have demonstrated that Epstein–Barr virus-associated gastric cancer (EBVaGC) patients showed a favorable clinical outcome to immunotherapy and Epstein–Barr virus (EBV)-positive status might be a potential biomarker for immu
Externí odkaz:
https://doaj.org/article/d69fcf92abe44295b7127c0cff6cb2ae
Publikováno v:
BMJ open. 12(7)
IntroductionThe optimal dose and treatment modality of neoadjuvant radiotherapy applied for treating borderline resectable and locally advanced pancreatic ductal adenocarcinoma (PDAC) have been debated topics in oncology. The objective of the present
Publikováno v:
Journal of Clinical Oncology. 40:e16244-e16244
e16244 Background: Much controversy remains regarding the immune-checkpoint-inhibitor plus Nab-paclitaxel/gemcitabine (AG) as the treatment in advanced pancreatic ductal adenocarcinoma (aPDAC). We assess safety and efficacy of toripalimab plus AG in
Autor:
Chen Chang, Xiaofen Li, Ke Cheng, Zhaolun Cai, Junjie Xiong, Wanrui Lv, Ruizhen Li, Pei Zhang, Dan Cao
Publikováno v:
Journal of Clinical Oncology. 40:e16261-e16261
Background Systemic chemotherapy is the primary treatment in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC). More effective treatment options are highly awaited. The aim of this study was to evaluate the toxicity